Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
Propanc Biopharma published new preclinical data showing its lead asset PRP remodels chemotherapy-resistant pancreatic cancer cells, reducing proliferation by ~50-54% and invasion by 47-81%, with EMT reversal and TGF-beta/SMAD pathway suppression. The data complement an earlier peer-reviewed pilot study in Scientific Reports reporting an 85.9% reduction in mean tumor weight in an orthotopic pancreatic model and >90% tumor growth inhibition with >2.5-fold survival extension in advanced PDAC models.
Key figures
- Drug Name
- PRP (fixed-ratio 1:6 intravenous formulation of trypsinogen and chymotrypsinogen)
- Phase Of Trial
- preclinical (Phase 1b First-in-Human planned Q1 2027)
- Invasion reduction
- 47-81%
- Phase1b enrollment
- up to 50 patients
- Proliferation reduction
- ~50-54% (PRP monotherapy)
- Median survival extension
- >2.5-fold
- Pan02 tumor weight reduction
- 85.9%
- Clonogenic survival reduction
- up to 59%
- Ovarian tumor weight inhibition
- ~50%
- Orthotopic PDX tumor growth inhibition
- >90%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.